Payaz Biomedikal VE Tibbi Cihazlar Pharmaceutical Import Profile — Turkey (DGFT 2022–2026)

Name: Payaz Biomedikal VE Tibbi Cihazlar Pharmaceutical Import Records from India — 5 Products, $11.8M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Payaz Biomedikal VE Tibbi Cihazlar — Pharmaceutical Importer Profile (2026) | 5 Products, $11.8M Trade | TransData Nexus

Payaz Biomedikal VE Tibbi Cihazlar

Pharmaceutical Importer · Turkey · Respiratory Focus · $11.8M Total Trade · DGFT Verified

Payaz Biomedikal VE Tibbi Cihazlar is a pharmaceutical importer based in Turkey with a total trade value of $11.8M across 5 products in 2 therapeutic categories. Based on 255 verified import shipments from Indian Customs (DGFT) records, Payaz Biomedikal VE Tibbi Cihazlar is the #1 buyer in 1 product including Salmeterol. Payaz Biomedikal VE Tibbi Cihazlar sources from 5 verified Indian suppliers, with Cipla Limited accounting for 81.3% of imports.

Payaz Biomedikal VE Tibbi Cihazlar — Import Portfolio & Supplier Network

Payaz Biomedikal VE Tibbi Cihazlar import network — 5 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Payaz Biomedikal VE Tibbi Cihazlar?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Cipla Limited	$10.1M	501	81.3%
Medispray Laboratories Private Limited	$1.5M	78	12.4%
Concord Biotech Limited

What Formulations Does Payaz Biomedikal VE Tibbi Cihazlar Import?

Formulation	Value	Ships
Flohale 250 hfa inhaler fluticasone	$856.6K	24
Seroflo 250 hfa inhaler (salmeterol xinafoate 25mcg+fluticasone propionate 250mcg ) (1 x 120 md)	$753.5K	17
Asthalin cfc free inhaler	$750.0K	15
Flohale 125 hfa inhaler (fluticasone	$571.6K	12
Seroflo 250 hfa inhaler salmeterol	$500.0K	10
Asthalin inhaler/dose counter	$436.6K	14
Imutrex 2.5MG TAB methotrexate 2.5MG	$400.0K	8
Seroflo 125 hfa inhaler (with dose indicator) (salmeterol xinafoate 25mcg+fluticasone propionate 125mcg ) (1 x 120 md)	$317.5K	7
Seroflo 125 hfa inhaler with dose	$300.0K	6
Flohale 125 hfa inhaler fluticasone	$200.0K	4
Fluticort plus -250 hfa inhaler with	$153.8K	4
Fluticort plus -250 hfa inhaler with dose indicator 120 md (salmeterol xinafoate 25 MCG + fluticasone propionate 250	$150.0K	3
Cytodrox 500 MG capsules (hydroxyurea	$134.1K	6
Ipravent 20 hfa inhaler 200md - iran -	$111.1K	3
Imutrex 2.5MG TAB(methotrexate 2.5MG	$100.0K	2

Payaz Biomedikal VE Tibbi Cihazlar imports 275 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 5 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Fluticasone	Respiratory	$4.8M	96	2.4%	3
2	Salmeterol	Respiratory	$3.3M	66	4.5%	1
3	Salbutamol	Respiratory	$2.5M	69	1.7%	6
4	Methotrexate	Immunosuppressants	$600.0K	12	1.7%	2
5	Tiotropium	Respiratory	$600.0K	12	0.9%	5

Payaz Biomedikal VE Tibbi Cihazlar imports 5 pharmaceutical products across 2 categories into Turkey totaling $11.8M. The company is the #1 buyer for 1 product: Salmeterol.

Payaz Biomedikal VE Tibbi Cihazlar — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Payaz Biomedikal ve Tıbbi Cihazlar İç ve Dış Ticaret Limited Şirketi, established on March 20, 2019, is a Turkish company headquartered in Istanbul. The company specializes in the wholesale distribution of medical, dental, and hospital equipment and supplies, serving a diverse clientele that includes hospitals, clinics, laboratories, and medical practitioners.

Since its inception, Payaz Biomedikal has positioned itself as a vital source for laboratory needs in Turkey's healthcare sector. The company emphasizes providing high-quality products at competitive prices, coupled with comprehensive after-sales support. Their product portfolio includes rapid tests, apheresis systems, laboratory tubes, and specialized storage suspensions, all sourced from reputable international manufacturers. (payaz.com.tr)

2Distribution Network

While specific details about Payaz Biomedikal's warehouse locations and logistics capabilities are not publicly disclosed, the company's operations are centralized in Istanbul, Turkey's commercial hub. This strategic location facilitates efficient distribution across the country, ensuring timely delivery to various healthcare institutions. The company's focus on high-quality products and after-sales support suggests a well-organized logistics network capable of meeting the demands of Turkey's healthcare sector.

3Industry Role

Payaz Biomedikal ve Tıbbi Cihazlar operates primarily as a wholesaler and distributor within Turkey's pharmaceutical supply chain. By sourcing medical and laboratory equipment from international suppliers and distributing them to local healthcare providers, the company plays a crucial role in ensuring the availability of essential medical supplies across the nation. Their emphasis on quality and customer support underscores their commitment to enhancing healthcare services in Turkey.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Payaz Biomedikal VE Tibbi Cihazlar

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Payaz Biomedikal's sourcing strategy exhibits a high degree of concentration, with a significant portion of their imports originating from India. This concentrated sourcing approach can offer benefits such as streamlined procurement processes and potentially better pricing due to bulk purchasing. However, it also introduces risks associated with over-reliance on a single source, including exposure to supply chain disruptions and geopolitical factors affecting trade relations. The company's substantial import volume from India indicates a stable and ongoing relationship, suggesting effective risk management strategies are in place to mitigate potential challenges.

2Supply Chain Resilience

The resilience of Payaz Biomedikal's supply chain is closely tied to its reliance on Indian suppliers. While this focus allows for specialization and potential cost advantages, it also means that any disruptions in Indian manufacturing or export policies could impact the company's ability to meet domestic demand. The company's diverse product portfolio, encompassing 275 unique formulations, indicates a level of flexibility in sourcing. However, the lack of publicly available information on backup suppliers and alternative sourcing strategies suggests that the company may benefit from diversifying its supplier base to enhance supply chain resilience.

Importing Pharmaceuticals into Turkey — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Turkey

1Regulatory Authority & Framework

In Turkey, the Ministry of Health (MoH) is the primary regulatory authority overseeing pharmaceutical imports. The importation of pharmaceutical products is governed by the "Regulation on Pharmaceutical and Medicinal Products," which outlines the requirements for obtaining import licenses and ensuring product quality. Additionally, the "Communiqué on Import of Certain Products that are Audited by the Ministry of Health" mandates that a certificate of control be obtained from the MoH before importing pharmaceutical products.

2Import Licensing & GMP

To import pharmaceutical products into Turkey, companies must obtain an import license from the MoH. This process involves submitting documentation such as pro forma invoices, certificates of analysis, and approved health certificates from the country of origin. The MoH requires that imported pharmaceutical products comply with recognized Good Manufacturing Practice (GMP) standards, including EU GMP, WHO GMP, or PIC/S certifications. Wholesale distributors must also obtain authorization from the MoH to operate legally within Turkey.

3Quality & Labeling

Payaz Biomedikal VE Tibbi Cihazlar — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Payaz Biomedikal's focus on respiratory medications and immunosuppressants aligns with the growing demand for treatments in these therapeutic areas. Respiratory diseases, including asthma and COPD, are prevalent in Turkey, driving the need for effective inhalation therapies. Immunosuppressants are essential for managing autoimmune conditions and organ transplant recipients, reflecting the company's commitment to addressing critical healthcare needs. By importing these specific categories, Payaz Biomedikal positions itself to meet significant market demands and contribute to improved patient outcomes.

2Sourcing Profile

Payaz Biomedikal's sourcing strategy emphasizes high-quality generic formulations, primarily sourced from India. This approach allows the company to offer cost-effective solutions without compromising on quality. The focus on finished pharmaceutical formulations, rather than raw APIs or bulk drugs, indicates a preference for ready-to-use products that can be directly distributed to healthcare providers. India's established pharmaceutical manufacturing capabilities and adherence to international GMP standards make it a suitable partner for this sourcing strategy.

3Market Positioning

Seller's Guide — How to Become a Supplier to Payaz Biomedikal VE Tibbi Cihazlar

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to collaborate with Payaz Biomedikal, especially in the respiratory and immunosuppressant categories. The company's concentrated sourcing strategy suggests potential for diversification, which could mitigate risks associated with over-reliance on a single supplier. Indian exporters can explore this opportunity by offering high-quality products that meet Turkish regulatory standards and align with Payaz Biomedikal's commitment to quality and customer support.

2Requirements & Qualifications

Indian exporters aiming to supply Payaz Biomedikal must ensure their products comply with Turkish regulatory requirements, including obtaining necessary import licenses and adhering to GMP standards recognized by the MoH. Products must undergo batch testing and meet stability requirements. Labeling must be in Turkish, with clear information on usage, dosage, and storage conditions. Serialization mandates must be met to ensure traceability and prevent counterfeit products. Establishing a partnership with Payaz Biomedikal also requires a commitment to quality and after-sales support, aligning with the company's operational standards.

How to Approach

Frequently Asked Questions — Payaz Biomedikal VE Tibbi Cihazlar

What products does Payaz Biomedikal VE Tibbi Cihazlar import from India?

Payaz Biomedikal VE Tibbi Cihazlar imports 5 pharmaceutical products across 2 categories. Top imports: Fluticasone ($4.8M), Salmeterol ($3.3M), Salbutamol ($2.5M), Methotrexate ($600.0K), Tiotropium ($600.0K).

Who supplies pharmaceuticals to Payaz Biomedikal VE Tibbi Cihazlar from India?

Payaz Biomedikal VE Tibbi Cihazlar sources from 5 verified Indian suppliers. The primary supplier is Cipla Limited (81.3% of imports, $10.1M).

What is Payaz Biomedikal VE Tibbi Cihazlar's total pharmaceutical import value?

Payaz Biomedikal VE Tibbi Cihazlar's total pharmaceutical import value from India is $11.8M, based on 255 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Payaz Biomedikal VE Tibbi Cihazlar focus on?

Payaz Biomedikal VE Tibbi Cihazlar imports across 2 categories. The largest: Respiratory (94.9%), Immunosuppressants (5.1%).

Get Full Payaz Biomedikal VE Tibbi Cihazlar Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.